A sensitive antiviral neutralization bioassay for measuring antibodies to interferons.
An improved bioassay for measuring neutralizing antibodies to interferons (IFN) is described. The assay is based upon an objective and precise quantification of the viral cytopathic effect. This effect is measured via the dehydrogenase-system in cells, and quantified spectrophotometrically. Virus-infected cells, in contrast to non-infected cells, possess low enzyme activity resulting in low OD signals. This fall in OD can be prevented by the addition of a small, but fixed amount of IFN before the addition of virus. Anti-IFN sera will neutralize the protective effect of IFN. This effect can be quantified by measurement of the reduction in the OD signals. Antibodies to recombinant IFN were found to cross-react with human leukocyte IFN although to a ten-fold lower degree. The assay requires no expensive reagents, it is performed in 96-well microtrays and the results can be measured in an ordinary ELISA scanner. The assay is highly reproducible, yielding inter- and intra-assay variability of less than 10%. The sensitivity is much higher than that reported previously for the CPE technique and that of ELISA techniques.
Institute of Medical Microbiology, University of Copenhagen, Denmark.
M B
MB
Hansen
C
C
Ross
K
K
Berg
D000818:Animals; D000906:Antibodies / Q000032:analysis*; D001681:Biological Assay / Q000379:methods*; D003588:Cytopathogenic Effect, Viral; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007372:Interferons / Q000032:analysis / Q000276:immunology*; D011817:Rabbits; D013778:Tetrazolium Salts; D013844:Thiazoles
D000906:Antibodies; D013778:Tetrazolium Salts; D013844:Thiazoles; D007372:Interferons; C022616:thiazolyl blue